Navigation Links
New drug shows promise against multiple sclerosis
Date:11/1/2011

An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America. It usually strikes young adults and is more common in women than in men.

The study, carried out by researchers at the University of California, San Francisco (UCSF) Medical Center, and involving hospitals in the United States, Canada, and Europe, is described this week in the British medical journal Lancet.

The study involved patients with relapsing-remitting MS, a form of the disease marked by the accumulation of lesions in the brain and spinal cord and periodic "attacks" of neurological impairment.

The 220 patients were randomly enrolled into four groups two that received injections of the monoclonal antibody Ocrelizumab at two different doses, one that received the standard multiple sclerosis drug interferon-beta, and one "control" group that was given a placebo.

The doctors gauged the effectiveness of each treatment by performing monthly magnetic resonance imaging (MRI) brain scans of the patients and counting the number of visible marks that indicate inflamed lesions, a hallmark of the disease. They also compared the severity and frequency of neurological "attacks" that cause loss of vision, incoordination, weakness and numbness, among other symptoms.

The results of this trial showed that patients who received the drug generally fared well and showed fewer signs of the disease than patients who receive a placebo or the standard Interferon treatment. Overall, the trial found that Ocrelizumab led to a 89 percent reduction in the formation of brain lesions, and it also reduced the number of new multiple sclerosis attacks over 24 weeks. During this relatively short-term study, interferon performed no better than placebo on these outcomes.

"It really is
'/>"/>

Contact: Jason Socrates Bardi
jason.bardi@ucsf.edu
415-502-4608
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Preterm birth rate shows three year improvement in most states
2. Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
3. Novel approach to treat proliferative vitreoretinopathy shows promise
4. New therapy shows promise for treating cardiovascular disease
5. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
6. New oncolytic virus shows improved effectiveness in preclinical testing
7. Clinical trial shows first evidence that anal cancer is preventable
8. Through-the-nipple breast cancer therapy shows promise in early tests
9. Compound found in common wart treatment shows promise as leukemia therapy
10. Study shows why underrepresented men should be included in binge eating research
11. HIV Medication Patch Shows Promise in Early Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... TransPack Toon gives users a set of 90 ... and framing transitions in 30 different styles. Presets range from snow, underwater, forest, futuristic, ... , TransPack Toon features 90 cartoon transitions from 30 unique styles. Editors can ...
(Date:9/3/2015)... ... 03, 2015 , ... The Beryl Institute announces 52 breakout ... held April 13-15 at Sheraton Hotel in Dallas, Texas. Patient Experience Conference is ... of healthcare leaders, staff, physicians, patients and families across the globe to convene, ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of ... for Healthcare Research and Policy Analysis has found physician leadership development training programs ... 47 percent of respondents said their organizations conduct some kind of physician leadership ...
(Date:9/3/2015)... ... September 03, 2015 , ... For many ... garments. However, graduated compression garments are an effective solution for reducing the medical ... Bjork, was recently sponsored by SIGVARIS for a unique opportunity to ...
(Date:9/3/2015)... ... ... Girl’s Night Out to benefit Core Compassion Project will be held on ... Monroe, North Carolina. The event food will be provided by Kate Clyde's ... off-premise catering and event services from casual to elegant. They are also the home ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 3Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 3Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2
... N.J., March 27 Zydus Pharmaceuticals announced today that ... and Drug Administration (FDA) for its Abbreviated New Drug ... and 200mg. This product is available for immediate ... patients 10 years old or older with partial onset ...
... Michigan, there are not enough jobs in manufacturing and ... to overshadow supply is health care, particularly physicians.The health ... difficulty of becoming a doctor have led to a ... projected to get worse, according to the Michigan State ...
... Stats show safety programs need to be extended to others ... (HealthDay News) -- Only one-third of people killed in fatal ... report shows. , The other two-thirds of victims are passengers, ... to the AAA Foundation for Traffic Safety. , "For every ...
... Women,s Voices for the Health Care We NeedNEW YORK, March ... debate the merits and costs of health reform, women around ... our families. For many women and our families, health reform ... York City will speak out publicly about the problems they ...
... of a program established in Uganda last year, the ... (HVO) have again partnered to launch a new hematology ... Empresa De Seguros De Salud (EsSalud). The goal of ... clinicians, laboratory technicians, technologists, and students. This training will ...
... unlocks the virus from latent state , , FRIDAY, March 27 ... in the ongoing quest for a treatment, and possibly a ... as VP16 is apparently responsible for pushing herpes out of ... , Experts estimate that 70 percent to 90 percent of ...
Cached Medicine News:Health News:As Physician Shortage Looms, Recognize Your Doctor On March 30, National Doctors' Day 2Health News:Most Fatalities in Teen Crashes Are Not the Drivers 2Health News:Women's Speak-Out for Action on Health Care Reform 2Health News:ASH and HVO Partner to Launch Hematology Program in Peru 2Health News:ASH and HVO Partner to Launch Hematology Program in Peru 3Health News:Treatment Target for Herpes Pinpointed 2
(Date:9/3/2015)... , Sept. 3, 2015  The findings of ... raising disturbing questions about the company,s handling of its ... reports.  On September 2 nd , part one ... adverse events, including at least 27 fatalities, have been ... a confidential study commissioned by C.R. Bard in 2004 ...
(Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4q3mv2/investigation ) ... on China Olmesartan Market, 2010-2019" report to their ... successfully developed by Sankyo Pharmaceuticals Co., Ltd and was ... was approved by FDA to enter the American market ... drug in the world after it succeeded in the ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ... the "Investigation Report on China Tamsulosin Market, ... Compared with other a1- adrenergic receptor blockers, ... and lower risk of urinary tract infections and ... its debut in 1993 in Japan ...
Breaking Medicine Technology:IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3China Olmesartan Investigation Market Report 2010-2019 2China Tamsulosin Market Investigation Report 2015 2
... 2010 ViroPharma Incorporated (Nasdaq: VPHM ) ... Cinryze ® (C1 esterase inhibitor [human]) at the ... (WAO), December 5 through 8 in Dubai, UAE.   ... these data, which were first presented at the November ...
... Healthcare, a world-leading developer, manufacturer and marketer of innovative ... that in connection with a refinancing of its debt ... in combination with new senior secured credit facilities, it ... Senior Notes. The offering of the new notes will ...
Cached Medicine Technology:Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 2Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 3Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 4Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 5Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 6Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 7Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 8Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 9ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 2ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 3
... Controls are liquid controls designed ... test procedures that detect Chlamydia ... they are specimen specific, they ... urine or endocervical/urethral swabs throughout ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
Medicine Products: